Oncotype DX® Recurrence Score as a Predictor of Response to Neoadjuvant Chemotherapy

被引：0
|
作者：
Alison M. Pease
Luis A. Riba
Ryan A. Gruner
Nadine M. Tung
Ted A. James
机构：
[1] Harvard Medical School,Department of Surgery, Beth Israel Deaconess Medical Center
[2] Harvard Medical School,Department of Surgery/Linsey BreastCare Center, Beth Israel Deaconess Medical Center
[3] Harvard Medical School,Department of Medicine/Division of Hematology – Oncology, Beth Israel Deaconess Medical Center
来源：
Annals of Surgical Oncology | 2019年 / 26卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：366 / 371
页数：5
相关论文
共 50 条
  • [21] Association of Insulin Resistance and Higher Oncotype DX™ Recurrence Score
    Nicole T. Gordon
    Jaime J. Alberty-Oller
    Kezhen Fei
    Giampaolo Greco
    Emily J. Gallagher
    Derek LeRoith
    Sheldon M. Feldman
    Bridgid Killilea
    Susan K. Boolbol
    Lydia Choi
    Neil Friedman
    Melissa Pilewskie
    Elisa Port
    Amy Tiersten
    Nina A. Bickell
    Annals of Surgical Oncology, 2021, 28 : 5941 - 5947
  • [22] Menopausal status does not predict Oncotype DX recurrence score
    Carr, Danielle N.
    Vera, Nora
    Sun, Weihong
    Lee, Marie Catherine
    Hoover, Susan
    Fulp, William
    Acs, Geza
    Laronga, Christine
    JOURNAL OF SURGICAL RESEARCH, 2015, 198 (01) : 27 - 33
  • [23] Oncotype DX Recurrence Score of Special Subtypes of Breast Carcinoma
    Ozerdem, Ugur
    Tavassoli, Fattaneh
    MODERN PATHOLOGY, 2017, 30 : 63A - 63A
  • [24] Oncotype DX Recurrence Score and treatment choices according to ethnicity
    Cruz, Allan Louie Espino
    Desale, Sameer
    Swain, Sandra M.
    Nunes, Raquel
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [25] Oncotype DX Recurrence Score of Special Subtypes of Breast Carcinoma
    Ozerdem, Ugur
    Tavassoli, Fattaneh
    LABORATORY INVESTIGATION, 2017, 97 : 63A - 63A
  • [26] Declining Utility of Oncotype Dx Recurrence Score with Advancing Age
    Iles, K. A.
    Roberson, M.
    Spanheimer, P. M.
    Gallagher, K. K.
    Ollila, D. W.
    Muss, H.
    Strassle, P. D.
    Downs-Canner, S.
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (SUPPL 1) : S63 - S63
  • [27] Validation of the Johns Hopkins oncotype DX recurrence score estimator
    Millado, Kristen
    Fogg, Louis
    Ghai, Ritu
    Cobleigh, Melody
    CANCER RESEARCH, 2020, 80 (04)
  • [28] 21-Gene Recurrence Score Index (ONCOTYPE DX) as a predictive biomarker for neoadjuvant chemotherapy response and outcome in patients with HR+HER2-breast cancer
    Cudos, Ariadna Gasol
    Murillo, Serafin Morales
    Der-Abrain, Noemi Tuset
    Villellas, Felip Vilardell
    Cid, Laura Arbones
    Olive, Jordi Mele
    Morales, Carles Canosa
    CANCER RESEARCH, 2024, 84 (09)
  • [29] Impact of OncoType DX™ Recurrence Score and Tumor Size on Making Chemotherapy Decisions in Breast Cancer Patients
    Goodwin, M. C.
    Hughes, J. H.
    Diego, M.
    Frazier, T. G.
    CANCER RESEARCH, 2009, 69 (24) : 835S - 835S
  • [30] Use of the 21-gene Oncotype DX® Breast Recurrence Score™ (RS) assay in the neoadjuvant treatment setting
    Robidoux, A.
    McCullough, D.
    Lau, A.
    Stoppler, M.
    Chao, C.
    BREAST, 2017, 32 : S80 - S80
12345